Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Hydrocortisone Valerate Cream USP, 0.2%, a generic version of Westcort 1 Cream, 0.2%, of Sun Pharmaceutical Industries Inc.

According to IQVIATM sales data for the 12-month period ending August 2018, the Westcort Cream, 0.2% market achieved annual sales of approximately USD 17.0 million.

Glenmark's current portfolio consists of 139 products authorized for distribution in the U.S. marketplace and 60 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of the company gained Rs 1, or 0.16%, to trade at Rs 617.00. The total volume of shares traded was 0 at the BSE (9.03 a.m., Tuesday).